期刊文献+

CD20在成年人急性B淋巴细胞白血病中的表达及其临床意义 被引量:2

Expression of CD20 in adult B-lineage acute iymphoblastic leukemia and its clinical significance
原文传递
导出
摘要 目的检测CD。在成年人急性B淋巴细胞白血病(B-ALL)的表达,探讨其与临床特点的相关性。方法回顾性总结分析96例成年B-ALL患者CD。表达情况,结合其临床特性和治疗转归进行分析。结果96例成年B-ALL患者中,CD。阳性29例(30.20%),CD。阴性67例(69.79%)。CD。阳性组与阴性组男女比分别为1.42:1和1.79:1(X^2=0.27,P〉0.05),中位年龄分别为28岁与23岁,肝脾及淋巴结浸润比例分别为44.83%和41.38%、40.30%和35.82%,髓系抗原表达比例分别为51.72%与56.72%,Ph染色体和bcr-abl融合基因阳性比例分别为24.14%与28.36%,4周内完全缓解率分别为73.08%与68.85%,差异均无统计学意义(P值均〉0.05)。在复发率和3年总体生存率上,CD。阳性组分别为54.55%与14.80%,CD。阴性组分别为29.63%与37.30%,两组问差异有统计学意义(X^2=0.42,X^2=5.31;P值均〈0.05)。结论CD。在成年人B-ALL表达与临床特点无相关性,但对判断患者的预后有一定的指导意义。 Objective To explore the clinical significance of expression of the CD20 in 96 adults B-lineage acute lymphoblastic leukemia (B-ALL). Methods The CD20 expression of 96 acute lymphoblastic leukenfia patients were determined by flow cytomeUy. The characteristics ,examination results and outcome were analyzed retrospectively. Results Out of the 96 patients, there were 29 (30.20 %) patients with CD20 positive and 67 (69.79 %) patients with CD20 negative. The distribution of age, infiltration of liver, spleen, and lymphnodes, the expression of myeloid lineage marker, the incidence of Ph chromosome and bcr-abl fusion gene and the complete remission rate within 4 weeks between CD20 positive and negative groups showed no significant differences (P 〉 0.05). The relapse rate and 3 year over survival rate of adults B-ALL in CD20 positive and negative groups were 54.55 % and 14.80 %, 29.63 % and 37.30 % respectively with a significant differences ( X^2 = 0.42, 5.31, P 〈 0.05). Conclusion The expression of CD20 in adult B-ALL appears to be not associated with clinical features and CD2o expression in adult B-ALL cells appears to be associated with poor prognosis.
出处 《白血病.淋巴瘤》 CAS 2011年第4期199-201,205,共4页 Journal of Leukemia & Lymphoma
基金 国家科技支撑计划(2008BAl61801)
关键词 白血病 B细胞 急性 抗原 CD20 免疫表型 Leukemia, B lineage, acute Antigens, CD2o Immunophenotype
  • 相关文献

参考文献10

  • 1Campana D.Role of minimal residnal disease monitoring in adult and pediatric acute lymphoblastic leukemia.Hematol Oncol Clin North Am,2009,23:1083-1098.
  • 2Gokbuget N,Hoelzer D.Treatment with monoclonal antibodies in acute lymphoblastic leukemia:current knowledge and future prospects.Ann Hematol,2004.83:201-205.
  • 3Czuczman MS,Olejniczak S,Gowda A,et al.Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at thepretranscriptional and posttranscriptional levels.Clin Cancer Res,2008,14:1561-1570.
  • 4Jazirehi AR,Vega MI,Bonavida B.Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.Cancer Res,2007,67:1270-1281.
  • 5Tbomas DA.O'Brien S,Jorgensen JI,et al.Prognostic significance of CD20 expression in adults with de nowo precursor B-lineage acute lymphoblastic leukemia.Blood,2009,113:6330-6337.
  • 6Maury S,Huguet F,Leguay T,et al.Adverse prognostic significanee of CD20 expression in adults with Philadelphia chromesome-negative B-cell precursor acute lymphoblastie leukemia.Haematologica,2010,95:324-328.
  • 7Chang H,Jiang A,Brandwein J.Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia.Haematologica,2010,95:1040-1042.
  • 8常乃柏.成年人急性淋巴细胞白血病方案优化与分层治疗[J].白血病.淋巴瘤,2010,19(10):580-583. 被引量:2
  • 9Thomas DA.O'Brien S,Faderl S,et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.J Clin Oncol,2010,28:3880-3889.
  • 10蔡宇,王椿,姜杰玲,杨隽,颜式可,万理萍.抗CD20单克隆抗体联合自体外周血干细胞移植治疗非霍奇金淋巴瘤的临床研究[J].白血病.淋巴瘤,2010,19(4):203-206. 被引量:2

二级参考文献37

  • 1蔡宇,王椿,杨隽,颜式可,蔡琦,高彦荣,姜杰玲.抗CD_(20)单克隆抗体在非霍奇金淋巴瘤治疗中的应用[J].白血病.淋巴瘤,2005,14(3):145-147. 被引量:8
  • 2孙丽霞,王金铠,常英军,张金巧.美罗华联合自体造血干细胞移植治疗高危复发非霍奇金淋巴瘤2例[J].临床内科杂志,2006,23(2):137-138. 被引量:1
  • 3Martelli M,Gheflinzoni F,De Renzo A,et al.Early autologous stem cell transplantation versus conventional chemotherapy as front-line therapy inhish-risk.aggressive non-hodgkin's lymphoma:an Italian multicenter randomized trial.J Clin Oncol,2003,21:1255-1262.
  • 4Liu AY,Robinson RR,Murray ED,et al.Production of a mousehuman chimeric monoclonal antibody to CD20 with potent Fcdependent biologic activity.J Immunol,1987,139:3521-3526.
  • 5LoBuglio AF,Wheeler RH,Trang J,et al.Mouse/human chimeric monoclonal antibody in man:Kinetics and immune response.Pro Natl Acad Sci USA,1989,86:4220-4224.
  • 6Mueller BM,Romerdahl Ca,Gillies SD,et al.Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.J immunol,1990,144:1382-1386.
  • 7Vose JM,Link BK,Grossbard ML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma.J Clin Oncol,2001,19:389-397.
  • 8Maloney DG,Smith B,Rose A.et al.Rituximab:mechanism of action and resistance.Semin Onod,2002,29:2-9.
  • 9Ladetto M,Corradini P,Vallet S,et al.High rate of clinical and molecular remissions in follicular lymphoma patients receiving highdose sequential chemotherapy and autografting at diagnosis:a multicenter,prospective study by the Gruppo ltaliano Trapianto Midollo Osseo (GITMO).Blood,2002,100:1559-1565.
  • 10Horwitz SM,Negrin RS,Blume KG,et al.Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.Blood,2004,103:777-783.

共引文献2

同被引文献13

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部